drug · protein
petrelintide
Phase 2updated 6mo agoby Zealand Pharma AS🔗 ChEMBL
Phase 2community read0 votes
Protein drug with a maximum clinical stage of Phase 2 (across all indications), with 2 investigational indications.
indications
indications
Obesity
all catalysts(0)
nothing on the calendar yet
Trials studying petrelintide
- phase3A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
- phase2Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
- phase2A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
- phase1Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations
- phase2Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
- phase1Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function
News(10)
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 3d ago
- Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage testThe Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk f…biospace · 7d ago
- Should amylin have been obesity therapeutics’ primary target from the start?While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 year…biospace · 29d ago
- Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugsObesity-focused Zealand Pharma is buying into Generate:Biomedicines’s generative AI platform to create new multispecific drug candidates.biospace · 1mo ago
- Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity raceRoche has committed $100 million in upfront and near-term payments to license Rona Therapeutics’ ALK7 drug candidate, joining Alnylam, Arrowhead, GSK and Novo Nordisk in an emerging obesity niche.fiercebiotech · 1mo ago
- FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analystsThe new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.biopharma_dive · 1mo ago
- Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacleZealand Pharma and Roche rolled out some mid-stage data for their amylin drug in obesity and diabetes, hoping to compete with Eli Lilly. In a Phase 2 study, petrelintide reduced patients’ ...endpoints · 1mo ago
- Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbersFor the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.biospace · 1mo ago
- Zealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar dataZealand Pharma has reported more phase 2 data on its Roche-partnered amylin analog, linking the drug candidate to competitive weight loss but a lackluster effect on blood sugar.fiercebiotech · 1mo ago
- 3 takeaways from a European obesity scientific meetingEli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…biopharma_dive · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that